AbbVie v. Fresenius Kabi: Five-Patent Ceftazidime-Avibactam Suit Transferred to D.N.J.
AbbVie and Allergan filed suit in the Northern District of Illinois against Fresenius Kabi, asserting five U.S. patents covering Ceftazidime and Avibactam for Injection (2 g/0.5 g). After 263 days, Judge Blakey ordered the case transferred to the District of New Jersey for coordinated pretrial proceedings before Judge Quraishi — a signal of parallel ANDA litigation already consolidated in that court.
Five-Patent Antibiotic Suit Finds Its Forum in New Jersey
On June 13, 2024, AbbVie, Inc. and its co-plaintiff Allergan Pharmaceuticals International Limited filed an infringement action in the Northern District of Illinois against Fresenius Kabi and its Italian affiliate Fresenius Kabi Ipsum SRL. The suit asserts five U.S. patents — US9695122B2, US8835455B2, US8471025B2, US9284314B2, and US8969566B2 — against Fresenius Kabi’s proposed generic Ceftazidime and Avibactam for Injection, 2 g/0.5 g per vial, a sterile powder formulation. Ceftazidime-avibactam is a last-resort antibiotic combination used against multidrug-resistant Gram-negative infections, marketed by AbbVie as Avycaz.
The case did not proceed to merits in Illinois. On March 3, 2025, Judge John Robert Blakey ordered the action transferred to the District of New Jersey, assigning it to the Honorable Zahid N. Quraishi for coordinated or consolidated pretrial proceedings. The transfer order explicitly references Schedule A, suggesting this was one of several parallel ANDA cases involving the same Avycaz patents already pending before Judge Quraishi in New Jersey — the recognised hub for multi-defendant pharmaceutical patent litigation of this type.
The 263-day timeline from filing to transfer is consistent with a Section 1407-style consolidation or a standing order coordinating related Hatch-Waxman suits. No substantive rulings on infringement, validity, or claim construction were issued in Illinois. The public record does not disclose whether Fresenius Kabi filed an ANDA with a Paragraph IV certification before or after the Illinois complaint, nor what specific invalidity arguments the defendant may have advanced. Prosecution of the five asserted patents — spanning application dates across multiple filing windows — will now be litigated centrally in New Jersey.
Filing to Case Transferred in 263 days
263 days from filing to transfer order — consistent with early-stage pretrial consolidation timelines in multi-defendant ANDA litigation
Case transferred to D.N.J.: what the venue change means for both parties
Transfer consolidates parallel ANDA suits in one forum
A transfer order in the Hatch-Waxman context typically reflects that a district court has identified overlapping patent and product issues across multiple ANDA defendants. Rather than litigating identical claim construction and validity questions in parallel courts, the transferee court — here, D.N.J. under Judge Quraishi — manages coordinated pretrial proceedings. No merits ruling was made in Illinois; all substantive disputes carry forward intact.
Coordinated pretrial — no merits decidedAbbVie retains all claims; litigation continues in New Jersey
The transfer does not prejudice AbbVie or Allergan. All five asserted patents remain in suit and the statutory 30-month stay protection under Hatch-Waxman is unaffected by a venue transfer. Consolidation in D.N.J. may actually benefit the patent holder by enabling a single, consistent claim construction ruling across all ANDA defendants simultaneously, reducing the risk of inconsistent outcomes.
All five patents still assertedFresenius Kabi now litigates in the pharmaceutical patent heartland
The District of New Jersey is the most active venue for Hatch-Waxman patent litigation in the United States. Fresenius Kabi and its affiliate will face proceedings before a judge with deep familiarity with pharmaceutical patent issues. Coordination with co-defendants — if any — may allow for shared invalidity arguments and prior art searches, but also means Fresenius Kabi cannot set the pace of litigation independently.
D.N.J. — high-volume pharma patent venueAvycaz patent wall faces coordinated challenge — market entry timing uncertain
Ceftazidime-avibactam (Avycaz) is a high-value antibiotic with significant hospital formulary penetration. With five patents spanning different aspects of the composition and formulation, AbbVie has constructed a layered exclusivity position. Consolidated proceedings in D.N.J. will determine whether any of these patents are invalid or not infringed by a generic formulation — an outcome that would directly affect branded pricing leverage and generic market entry timing.
Generic entry timing unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Global biopharmaceutical company — holder of US9695122B2 and 4 further Avycaz patentsSearch in Eureka ↗ |
| Co-Plaintiff | Allergan Pharmaceuticals International Limited | Individual | Search in Eureka ↗ |
| Defendant | Fresenius Kabi | Individual | Generic pharmaceutical manufacturer and Italian affiliate challenging Avycaz patent exclusivitySearch in Eureka ↗ |
| Co-Defendant | FRESENIUS KABI IPSUM SRL | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Lisa Lynn Furby | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Jones Day | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew V. Anderson | Attorney | Counsel for Fresenius KabiSearch in Eureka ↗ |
| Defendant counsel | William Andrew Rakoczy | Attorney | Counsel for Fresenius KabiSearch in Eureka ↗ |
| Defendant law firm | Rakoczy, Molino, Mazzochi, Siwik LLP | Law Firm | Representing Fresenius KabiSearch in Eureka ↗ |
| Presiding judge | Judge John Robert Blakey | Judge | Illinois Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The transfer order is procedural and carries no merits determination. Judge Blakey’s reference to ‘the action listed on Schedule A’ confirms this Illinois case is one of multiple related filings, and that the decision to consolidate reflects judicial economy rather than any assessment of patent strength or ANDA validity. For both parties, the operative litigation now proceeds entirely in the District of New Jersey before Judge Quraishi, where all claim construction, discovery, and validity disputes will be adjudicated under a single coordinated schedule.
US9695122B2 and four further Avycaz patents — Ceftazidime-Avibactam injection
The five asserted patents — US9695122B2, US8835455B2, US8471025B2, US9284314B2, and US8969566B2 — collectively cover multiple layers of the Ceftazidime and Avibactam for Injection product known commercially as Avycaz. The application dates span from 2010 (US8471025B2, App. No. 12/900567) through to 2016 (US9695122B2, App. No. 15/040654), reflecting a prosecution strategy designed to extend exclusivity across different aspects of the drug: compound chemistry, formulation, and potentially method-of-use claims. Avycaz is a combination of a cephalosporin antibiotic and a novel beta-lactamase inhibitor developed to combat resistant Gram-negative bacteria.
The breadth of the patent estate — five patents with staggered priority dates — creates a formidable exclusivity wall around Avycaz. Competitors seeking to enter the ceftazidime-avibactam generic market must navigate invalidity or non-infringement arguments against each patent independently. The earliest-filed patents may be more vulnerable to prior art challenges given the academic and clinical literature on beta-lactamase inhibitors that predates some filing dates. Any successful IPR petition against even one compound claim patent could materially alter the generic entry timeline and AbbVie’s pricing power in a hospital antibiotic segment where Avycaz commands premium positioning.
Should you run an FTO against the five Avycaz patents?
Any company developing, manufacturing, or commercialising a generic Ceftazidime-Avibactam for Injection product in the United States should treat these five patents as active enforcement risk. AbbVie has demonstrated willingness to assert the full portfolio simultaneously against a single ANDA filer, and consolidation in D.N.J. means claim construction rulings will bind all challengers. R&D teams exploring alternative avibactam salt forms, crystal polymorphs, or reconstitution formulations should conduct FTO analysis before advancing to IND or ANDA submission.
PatSnap Eureka’s FTO Search Agent can map each of the five asserted patents to their independent claims, identify prosecution history disclaimers, and flag prior art that may support non-infringement or invalidity positions. Eureka’s claim charting tools allow your team to assess whether a proposed generic formulation falls within the literal scope of US9695122B2, US8835455B2, US8471025B2, US9284314B2, or US8969566B2 — before you commit to an ANDA filing strategy.
Run a freedom-to-operate analysis on US9695122B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving ceftazidime-avibactam and antibiotic formulation patents
Related Hatch-Waxman cases asserting antibiotic combination patents in the District of New Jersey and other pharmaceutical-heavy courts, involving ceftazidime-avibactam or comparable beta-lactam/inhibitor combinations.
What this case signals for the Hatch-Waxman antibiotic IP landscape
AbbVie’s five-patent Avycaz assertion and its rapid consolidation in D.N.J. reflects how originator pharma companies defend layered antibiotic exclusivity.
Multi-patent ANDA stacking remains a core Avycaz defence strategy
AbbVie has asserted five patents with distinct application dates against a single generic entrant. This layered approach — spanning composition, formulation, and method claims — forces ANDA challengers to invalidate or design around multiple claim sets simultaneously, raising the cost and complexity of generic entry.
D.N.J. consolidation signals likely multi-defendant ANDA wave for Avycaz
The transfer to Judge Quraishi for ‘coordinated or consolidated pretrial proceedings’ suggests additional ANDA filers are already in suit in New Jersey. Companies monitoring generic ceftazidime-avibactam development should track D.N.J. dockets for claim construction rulings that will set the validity baseline for all challengers.
AbbVie v Fresenius — key questions answered
AbbVie and Allergan asserted five U.S. patents: US9695122B2, US8835455B2, US8471025B2, US9284314B2, and US8969566B2. All relate to Ceftazidime and Avibactam for Injection (2 g/0.5 g per vial, sterile powder), the branded product marketed as Avycaz. The complaint was filed in the Northern District of Illinois on June 13, 2024.
Judge John Robert Blakey ordered the transfer on March 3, 2025, directing that the case be assigned to Judge Zahid N. Quraishi in the District of New Jersey for coordinated or consolidated pretrial proceedings. The transfer order references a Schedule A, suggesting parallel ANDA litigation involving the same Avycaz patents was already pending in D.N.J., making consolidation the judicially efficient outcome.
The product at issue is Ceftazidime and Avibactam for Injection, 2 g/0.5 g per vial, a sterile powder formulation. This is the generic equivalent of AbbVie’s branded antibiotic Avycaz, used to treat multidrug-resistant Gram-negative bacterial infections in hospital settings. Fresenius Kabi’s proposed generic is the subject of an ANDA filing that triggered the Hatch-Waxman suit.
No. The Northern District of Illinois issued no substantive ruling on infringement, validity, or claim construction. The sole dispositive order was the March 3, 2025 transfer to the District of New Jersey. All merits questions — including whether Fresenius Kabi’s proposed generic infringes any of the five asserted patents — will be decided by Judge Quraishi in D.N.J.
AbbVie and Allergan are represented by Jones Day, with Lisa Lynn Furby listed as plaintiff counsel of record. Fresenius Kabi is represented by Rakoczy, Molino, Mazzochi, Siwik LLP, with Matthew V. Anderson and William Andrew Rakoczy listed as defence counsel. Rakoczy Molino is a specialist ANDA litigation boutique with extensive Hatch-Waxman experience.
PatSnap Eureka searches patents and litigation data to answer instantly.